SML4024
PZ-1922
≥95% (HPLC)
别名:
1-(3-Chlorobenzyl)-4-(piperazin-1-yl)-1H-pyrrolo[3,2-c]quinoline hydrochloride, 1-[(3-Chlorophenyl)methyl]-4-(1-piperazinyl)-1H-pyrrolo[3,2-c]quinoline hydrochloride, PZ 1922 hydrochloride, PZ1922 hydrochloride
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H21ClN4 · xHCl
化学文摘社编号:
分子量:
376.88 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.21
InChI key
MFUVKDHSDIAPMH-UHFFFAOYSA-N
SMILES string
ClC1=CC(CN2C=CC3=C2C4=CC=CC=C4N=C3N5CCNCC5)=CC=C1
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Bioavailable triple acting, selective, high affinity 5-HT6R/5-HT3R dual antagonist and MAO-B reversible inhibitor; anti-AD agent.
PZ-1922 is a piperazinyl-pyrroloquinoline analog with favorable oral absorption and CNS penetration that simultaneously targets 5-HT6R (Ki = 17 nM), 5-HT3R (Ki = 0.45 nM), and MAO-B (pIC50 = 8.93). PZ1922 shows high selectivity over a selected panel of GPCRs, MAO-A and hERG. PZ 1922 effectively reverses cognitive impairment, prevents Aβ-induced memory decline in rodent models of Alzheimer’s disease (AD) (1.5 mg/kg/ip injection) and modulates neuroinflammatory processes.
PZ-1922 is a piperazinyl-pyrroloquinoline analog with favorable oral absorption and CNS penetration that simultaneously targets 5-HT6R (Ki = 17 nM), 5-HT3R (Ki = 0.45 nM), and MAO-B (pIC50 = 8.93). PZ1922 shows high selectivity over a selected panel of GPCRs, MAO-A and hERG. PZ 1922 effectively reverses cognitive impairment, prevents Aβ-induced memory decline in rodent models of Alzheimer’s disease (AD) (1.5 mg/kg/ip injection) and modulates neuroinflammatory processes.
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Katarzyna Grychowska et al.
Journal of medicinal chemistry, 66(21), 14928-14947 (2023-10-05)
The multifactorial origin and neurochemistry of Alzheimer's disease (AD) call for the development of multitarget treatment strategies. We report a first-in-class triple acting compound that targets serotonin type 6 and 3 receptors (5-HT-Rs) and monoamine oxidase type B (MAO-B) as
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持